46 results about "Staurosporine" patented technology

The invention discloses a culture medium which is applicable to culturing staurosporine producing bacteria for producing staurosporine; the culture medium with pH value of 7.0 comprises carbon sources, organic nitrogen sources and inorganic salt, wherein, the inorganic salt comprises calcium salt; the carbon sources are selected from two or more than two of the following three groups of components, namely, A, B and C, wherein, at least two components are selected from different groups, group A: glucose, group B: amidulin, corn starch and potato starch, and group C: oats and maltodextrin; and / or, the organic nitrogen sources are selected from soybean cake powder, yeast extract, yeast cream and kapok meal; and / or, the inorganic salt is also added with magnesium salt. The invention also discloses a method for producing staurosporine from staurosporine producing bacteria by adopting the culture medium. By adopting the fermentation medium for producing staurosporine, the thalli of the staurosporine producing bacteria grows fast, the mycelia are not easy to clot, the yield of fermentation products is high, and the relative potency is optimized 230 percent of a former culture medium.

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

The invention provides a method for promoting the accumulation of staurosporine, and specifically discloses a culture medium for promoting the accumulation of staurosporine, which greatly promotes the accumulation of staurosporine by adopting different vitamin combinations and medium formulas. At the same time, by adding carbon source, the fermentation yield can be increased by more than 40%. The technical scheme provided by the invention is simple and feasible, further improves the production efficiency of the staurosporine, reduces production costs, and facilitates the industrial production and application of the staurosporine.

The invention discloses a 7-carbonyl staurosporine compound, and a preparation method and an application thereof. The staurosporine compound provided by the invention has a structural formula as shownin a formula (I) which is described in the specification. The staurosporin compound provided by the invention is prepared through the following steps: subjecting actinomycete to fermentation in a rice solid medium, then carrying out extraction and filtration so as to obtain a crude extract, and carrying out separation and purification. The staurosporin compound provided by the invention has significant antitumor activity, specifically has high activity to prostate cancer, colon cancer, pancreatic cancer and gastric cancer, and can be used for preparation of anticancer drugs.

The invention relates to phylum porifera symbiosis streptomycete SP6206, belonging to the field of phylum porifera symbiosis streptomycete fermentation. The preservation number of the phylum poriferasymbiosis streptomycete SP6206 is CCTCCM2017451. The invention also discloses a method for producing staurosporine by fermenting the phylum porifera symbiosis streptomycete SP6206, which comprises thefollowing steps: (1) culturing a seed solution of the SP6206; (2) inoculating the cultured seed solution of the SP6206 to a fermenting culture substrate, and carrying out fermented culture, thereby obtaining a fermentation solution; and (3) separating staurosporine from the fermentation solution. According to the phylum porifera symbiosis streptomycete SP6206, the highest yield of the staurosporine reaches 320mg / L and is greatly increased compared with that of the common wild streptomycete staurosporine in the prior art. The staurosporine can be used for preventing and treating the colletotrichum gloeosporioides of Chinese yams, the minimal inhibitory concentration of the staurosporine for preventing and treating the colletotrichum gloeosporioides of the Chinese yams is 8 microg / ml, and the minimal inhibitory concentration of the staurosporine is 1 / 4 that of the positive drug cycloheximide.

This invention relates to a semisolid ophthalmic composition, in particular an ointment, comprising (1) an ophthalmic drug, e. g. a staurosporine derivative, (2) an ointment base and (3) an agent for dispersing and / or dissolving said drug in the ointment base, selected from a poly(ethylene-glycol), a polyethoxylated castor oil, an alcohol having 12 to 20 carbon atoms and a mixture of two or more of said components.

The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein. In various embodiments, the present invention contemplates a kit comprising an agent that increases prostaglandin EP receptor signaling and staurosporine.